Mounjaro Emerges as India’s Leading Drug, Achieving ₹100 Crore in October Sales

Post by : Saif Nasser

Mounjaro, the obesity and diabetes medication from Eli Lilly, has secured its position as the top-selling drug in India for October, generating ₹100 crore (approximately $11.38 million) in sales within just one month. Launched in March 2025, the drug has seen a remarkable increase in popularity. This surge signifies a marked interest among the Indian population in effective solutions to combat diabetes and obesity. Recent research published in The Lancet indicates that around 11.4 percent of India’s population, equating to roughly 101 million people, are living with diabetes.

This injectable treatment is specifically tailored for individuals with type 2 diabetes who either struggle with being overweight or obese. Mounjaro acts by influencing two vital hormones, GLP-1 and GIP, which are essential in managing blood sugar levels and appetite, facilitating healthier weight management. Medical professionals assert that by regulating digestion and suppressing hunger, Mounjaro effectively supports sustainable weight loss.

Since its introduction, Mounjaro has significantly outpaced its competitor, Wegovy from Novo Nordisk, which was released in June. In October, Mounjaro’s usage in India surpassed that of Wegovy by a staggering tenfold. The medication has accrued revenues totaling ₹333 crore since its March launch. Moreover, research indicates that tirzepatide, the active ingredient in Mounjaro, may lead to greater weight loss than semaglutide, known commercially as Ozempic.

While Mounjaro has proven to be effective, experts advise that it should not be viewed as a universal quick fix. It is essential for patients, particularly those with diabetes or other underlying health challenges, to use this drug under professional supervision. The success of Mounjaro underscores the increasing necessity for dual-function treatments that address both weight management and blood sugar control in India. With the prevalence of diabetes and obesity on the rise, drugs such as Mounjaro are becoming integral components of healthcare strategies.

The expanding popularity of the drug reflects a growing health consciousness among the populace, where individuals are eager to pursue treatments that enhance their lifestyle. Nonetheless, medical experts emphasize that complementary lifestyle adjustments—such as nutritious eating habits, consistent physical activity, and balanced nutrition—remain crucial alongside any therapeutic intervention.

The swift ascent of Mounjaro illustrates a burgeoning trend in India, marking a surge in demand for modern pharmaceuticals targeted at obesity and diabetes, highlighting the nation’s quest for safe and effective health management solutions for its vast population.